English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA new study led by researchers at The University of Texas MD Anderson Cancer Center discovered that co-occurring mutations in three tumor suppressor genes – KEAP1, SMARCA4 and CDKN2A – are linked with poor clinical outcomes in patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) treated with the KRAS G12C inhibitors adagrasib or sotorasib.
Tag: AACR 2023 Annual Meeting
AACR: Penn Medicine Preclinical Study Identifies New Target for Recurrent Ovarian Cancer
Results from a preclinical study from Penn Medicine, presented at the AACR Annual Meeting 2023, verified a new target for drug-resistant ovarian cancer and provided data to support a treatment approach that is already making its way into clinical trials.
AACR: Lung cancer outcomes significantly improved with immunotherapy-based treatment given before and after surgery
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to Phase III trial results presented today by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2023.
St. Jude scientists to receive coveted awards at AACR annual meeting
The American Association of Cancer Research (AACR) will honor two investigators from St. Jude Children’s Research Hospital for their research contributions. Melissa Hudson, M.D., director of the Cancer Survivorship Division and Jun J. Yang, Ph.D., vice-chair of Pharmacy and Pharmaceutical Sciences